Immunome, Inc. (NASDAQ:IMNM) Stock Holdings Cut by Point72 Asset Management L.P.

Point72 Asset Management L.P. lessened its position in Immunome, Inc. (NASDAQ:IMNM) by 76.5% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 385,067 shares of the company’s stock after selling 1,256,833 shares during the period. Point72 Asset Management L.P. owned approximately 0.64% of Immunome worth $4,659,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of IMNM. Avidity Partners Management LP bought a new stake in Immunome in the fourth quarter worth about $14,268,000. Price T Rowe Associates Inc. MD grew its stake in shares of Immunome by 113.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,245,673 shares of the company’s stock worth $55,425,000 after purchasing an additional 1,194,451 shares during the last quarter. Marshall Wace LLP raised its holdings in shares of Immunome by 228.5% in the 2nd quarter. Marshall Wace LLP now owns 1,713,325 shares of the company’s stock worth $20,731,000 after purchasing an additional 1,191,774 shares in the last quarter. Redmile Group LLC lifted its stake in Immunome by 26.0% during the first quarter. Redmile Group LLC now owns 4,889,554 shares of the company’s stock valued at $120,674,000 after purchasing an additional 1,010,139 shares during the last quarter. Finally, Farallon Capital Management LLC bought a new stake in Immunome during the first quarter worth approximately $14,660,000. Institutional investors own 44.58% of the company’s stock.

Insider Buying and Selling

In other Immunome news, insider Jack Higgins sold 3,524 shares of Immunome stock in a transaction dated Thursday, August 15th. The stock was sold at an average price of $13.93, for a total transaction of $49,089.32. Following the transaction, the insider now owns 16,000 shares of the company’s stock, valued at approximately $222,880. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, Director Jean Jacques Bienaime acquired 7,000 shares of the company’s stock in a transaction on Friday, August 16th. The shares were purchased at an average price of $13.94 per share, for a total transaction of $97,580.00. Following the purchase, the director now owns 16,615 shares in the company, valued at $231,613.10. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Jack Higgins sold 3,524 shares of Immunome stock in a transaction on Thursday, August 15th. The shares were sold at an average price of $13.93, for a total transaction of $49,089.32. Following the sale, the insider now directly owns 16,000 shares of the company’s stock, valued at approximately $222,880. The disclosure for this sale can be found here. Company insiders own 8.60% of the company’s stock.

Immunome Stock Performance

Shares of NASDAQ:IMNM opened at $13.52 on Wednesday. The firm has a 50 day simple moving average of $14.57 and a 200 day simple moving average of $15.54. Immunome, Inc. has a 52 week low of $6.93 and a 52 week high of $30.96. The company has a market cap of $810.78 million, a PE ratio of -1.79 and a beta of 1.77.

Immunome (NASDAQ:IMNM) last released its earnings results on Monday, August 12th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.11). Immunome had a negative net margin of 2,435.02% and a negative return on equity of 38.19%. The business had revenue of $2.36 million during the quarter, compared to analysts’ expectations of $2.62 million. On average, equities analysts predict that Immunome, Inc. will post -1.92 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the company. Wedbush reaffirmed an “outperform” rating and issued a $33.00 price target on shares of Immunome in a report on Tuesday, August 13th. Piper Sandler cut their target price on Immunome from $27.00 to $23.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 13th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $29.00.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.